Images List Premium Download Classic

Immunotherapy

Immunotherapy-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Method for modulating car-induced immune cells activity
Cellectis
October 12, 2017 - N°20170292118

The present invention relates to a method to modulate the level of activation of an engineered immune cell (such as a chimeric antigen receptor t-cell) for immunotherapy. The present invention also relates to cells obtained by the present method, preferably comprising said modulable/tunable chimeric antigen receptors for use in therapeutic or prophylactic treatment.
Anti pd-l1 conjugates for treating tumors
Birdie Biopharmaceuticals, Inc.
October 12, 2017 - N°20170290923

The present invention discloses anti-pd-l/pd-1 axis antibody conjugates for targeted immunotherapy, as well as compositions comprising said conjugates. Further, the present invention discloses the use of the conjugates in the treatment of tumor/cancer.
Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by ...
Sotio A.s.
October 12, 2017 - N°20170290899

Disclosed are pharmaceutical compositions for inducing an immune response against tumor cells comprising tumor cells which are made apoptotic by treatment with high hydrostatic pressure and dendritic cells, and methods for producing such compositions.
Immunotherapy Patent Pack
Download 225+ patent application PDFs
Immunotherapy Patent Applications
Download 225+ Immunotherapy-related PDFs
For professional research & prior art discovery
inventor
  • 225+ full patent PDF documents of Immunotherapy-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Kit for increasing th1 cells
Immunovative Therapies, Ltd.
October 12, 2017 - N°20170290857

The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a th1 footprint in normal individuals or patients susceptible to disease or having minimal residual disease.
Car-expressing nk-92 cells as cell therapeutic agents
Drk Blutspendedienst Baden-wurttemberg-hessen Ggmbh
October 05, 2017 - N°20170283507

The present invention relates to an erbb2-specific nk-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the erbb2-specific nk-92 cell or cell line in the prevention and/or treatment of cancer, preferably erbb2-expressing ...
Ror1 (ntrkr1) specific chimeric antigen receptors for cancer immunotherapy
Cellectis
October 05, 2017 - N°20170283497

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from a ror1 monoclonal antibody, conferring specific immunity against ror1 positive cells. The engineered immune cells endowed with such cars are particularly ...
Immunotherapy Patent Pack
Download 225+ patent application PDFs
Immunotherapy Patent Applications
Download 225+ Immunotherapy-related PDFs
For professional research & prior art discovery
inventor
  • 225+ full patent PDF documents of Immunotherapy-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Targeting immunotherapy for amyloidosis
University Of Tennessee Research Foundation
October 05, 2017 - N°20170281807

Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject. Antibodies to the amyloid-reactive peptides are then administered to the subject. Upon administration of the antibodies, the amyloid-reactive peptides bind the antibodies and thus pre-target the antibodies to the amyloid deposits. In other examples, an amyloid-reactive ...
Th1 vaccination priming for active immunotherapy
Immunovative Therapies, Ltd.
October 05, 2017 - N°20170281743

The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a th1 footprint in normal individuals or patients susceptible to disease or having minimal residual disease.
Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy
Baylor College Of Medicine
October 05, 2017 - N°20170281683

Embodiments of the disclosure include methods and compositions related to immunotherapy that targets glypican-3. In particular embodiments, immune cells engineered to comprise a chimeric antigen receptor that targets glypican-3 are contemplated, and uses thereof. In particular embodiments, medical conditions that are associated with glypican-3 expression or an overexpression of glypican-3 are treated with gpc3 cars.
Chimeric receptors and uses thereof in immune therapy
Unum Therapeutics Inc.
October 05, 2017 - N°20170281682

Disclosed herein are chimeric receptors comprising an extracellular domain with affinity and specific for the fc portion of an immunoglobulin molecule (ig), an fc-binding domain; a transmembrane domain; at least one co-stimulatory signaling domain; and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (itam). Also provided herein are nucleic acids encoding such chimeric receptors and immune cells expressing ...
Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
Cellectis
September 28, 2017 - N°20170275374

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from a 5t4 monoclonal antibody, conferring specific immunity against 5t4 positive cells. The engineered immune cells endowed with such cars are particularly ...
Egfrviii specific chimeric antigen receptor for cancer immunotherapy
Pfizer Inc.
September 28, 2017 - N°20170275366

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from an egfrviii monoclonal antibody, conferring specific immunity against egfrviii positive cells. The tcr ko engineered immune cells endowed with such cars ...
Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
Compugen Ltd.
September 28, 2017 - N°20170275344

This invention, in at least some embodiments, relates to a protein c1orf32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders.
Immunotherapy Patent Pack
Download 225+ patent application PDFs
Immunotherapy Patent Applications
Download 225+ Immunotherapy-related PDFs
For professional research & prior art discovery
inventor
  • 225+ full patent PDF documents of Immunotherapy-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3...
Immunomedics, Inc.
September 28, 2017 - N°20170274093

The present invention relates to combination therapy with drugs, such as microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or pi3k inhibitors, with antibodies or immunoconjugates against hla-dr or trop-2. Where immunoconjugates are used, they preferably incorporate sn-38 or pro-2pdox. The immunoconjugate may be administered at a dosage of between 1 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, ...
Immunotherapy for the treatment of cancer
University Health Network
September 28, 2017 - N°20170274060

Methods for the treatment of cancer using double negative (dn) t cells are described. The dnts may be used for the treatment of chemotherapy-resistant cancers such as recurring or relapsing acute myeloid leukemia (aml). The use of allogenic dnts, such as those derived from healthy donors, that do not exhibit toxicity towards normal host tissues and the complications associated with ...
Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating ...
Globeimmune Inc.
September 21, 2017 - N°20170271136

A method and system for predicting in advance of treatment whether a cancer patient is likely, or not likely, to obtain benefit from administration of a yeast-based immune response generating therapy, which may be yeast-based immunotherapy for mutated ras-based cancer, alone or in combination with another anti-cancer therapy. The method uses mass spectrometry of a blood-derived patient sample and a ...
Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells
Globeimmune Inc.
September 21, 2017 - N°20170267974

Disclosed herein are new methods of producing a novel line of dendritic cells. The method comprises subjecting a sample of hematopoietic stem/precursor cells to a first feeder culture system that is supplemented with a first set of factors and a second feeder culture system supplemented with a second group of factors. The disclosure also pertains to new cell types ...
Immunotherapy with binding agents
Oncomed Pharmaceuticals, Inc.
September 21, 2017 - N°20170267758

Binding agents that modulate the immune response are disclosed. The binding agents may include antibodies, soluble receptors, and/or polypeptides. Also disclosed are methods of using the binding agents for the treatment of diseases such as cancer.
Tagged chimeric effector molecules and receptors thereof
Fred Hutchinson Cancer Research Center
September 21, 2017 - N°20170267756

The present disclosure relates to tagged chimeric effector molecules and receptor molecules thereof for genetically engineering a host cell, wherein the recombinant host cell can be identified, isolated, sorted, induced to proliferate, tracked or eliminated using the tag. An exemplary receptor molecule is a chimeric antigen receptors (cars) having an extracellular domain comprising a binding domain for a target, a ...
Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
Immatics Biotechnologies Gmbh
September 21, 2017 - N°20170267738

Disclosed are t-cell receptors (tcrs) binding to tumor-associated antigens (taas) for targeting cancer cells, t-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are tcrs and their variants that bind to hla class i or ii molecules with a peptide, such as mag-003 have the amino acid sequence of kvlehvvrv (seq id no:1). The ...
Glypican-3-specific t-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
Technische Universität München
September 21, 2017 - N°20170267737

The present invention relates to glypican-3-specific t-cell receptors. The present invention further relates to soluble tcr constructs, chimeric tcrs, bi-specific antibodies, nucleic acids, expression constructs and cells comprising said tcrs or tcr constructs. The present invention further relates to the use of the tcr or the soluble tcr constructs or chimeric tcrs or bi-specific antibodies as a medicament, preferably ...
Loading